About RasGAP-activating-like protein 1
RasGAP-activating-like protein 1 (RASAL1) is a protein
from Homo sapiens identified by UniProt accession
O95294, 804 residues long.
MolForge cross-references it against 0 known binders and
91 disease associations.
Target properties
| Protein name | RasGAP-activating-like protein 1 |
|---|
| UniProt accession | O95294 |
|---|
| Gene | RASAL1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 804 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O95294-F1 | alphafold | PREDICTED | 88.18 | — |
Amino-acid sequence (804 residues)
MAKSSSLNVR VVEGRALPAK DVSGSSDPYC LVKVDDEVVA RTATVWRSLG PFWGEEYTVH LPLDFHQLAF YVLDEDTVGH DDIIGKISLS REAITADPRG IDSWINLSRV DPDAEVQGEI CLSVQMLEDG QGRCLRCHVL QARDLAPRDI SGTSDPFARV FWGSQSLETS TIKKTRFPHW DEVLELREMP GAPSPLRVEL WDWDMVGKND FLGMVEFSPK TLQQKPPKGW FRLLPFPRAE EDSGGNLGAL RVKVRLIEDR VLPSQCYQPL MELLMESVQG PAEEDTASPL ALLEELTLGD CRQDLATKLV KLFLGRGLAG RFLDYLTRRE VARTMDPNTL FRSNSLASKS MEQFMKLVGM PYLHEVLKPV ISRVFEEKKY MELDPCKMDL GRTRRISFKG ALSEEQMRET SLGLLTGYLG PIVDAIVGSV GRCPPAMRLA FKQLHRRVEE RFPQAEHQDV KYLAISGFLF LRFFAPAILT PKLFDLRDQH ADPQTSRSLL LLAKAVQSIG NLGQQLGQGK ELWMAPLHPF LLQCVSRVRD FLDRLVDVDG DEAGVPARAL FPPSAIVREG YLLKRKEEPA GLATRFAFKK RYVWLSGETL SFSKSPEWQM CHSIPVSHIR AVERVDEGAF QLPHVMQVVT QDGTGALHTT YLQCKNVNEL NQWLSALRKA SAPNPNKLAA CHPGAFRSAR WTCCLQAERS AAGCSRTHSA VTLGDWSDPL DPDAEAQTVY RQLLLGRDQL RLKLLEDSNM DTTLEADTGA CPEVLARQRA ATARLLEVLA DLDRAHEEFQ QQERGKAALG PLGP
Explore RasGAP-activating-like protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets